Invention Grant
US07667030B2 RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
有权
使用短干扰核酸(siNA)的RNA干扰介导的基质金属蛋白酶13(MMP13)基因表达的抑制
- Patent Title: RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
- Patent Title (中): 使用短干扰核酸(siNA)的RNA干扰介导的基质金属蛋白酶13(MMP13)基因表达的抑制
-
Application No.: US12204612Application Date: 2008-09-04
-
Publication No.: US07667030B2Publication Date: 2010-02-23
- Inventor: James McSwiggen , Leonid Beigelman
- Applicant: James McSwiggen , Leonid Beigelman
- Applicant Address: US CA San Francisco
- Assignee: Sirna Therapeutics, Inc.
- Current Assignee: Sirna Therapeutics, Inc.
- Current Assignee Address: US CA San Francisco
- Agent Elaine C. Stracker
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C07H21/02 ; A61K48/00

Abstract:
This invention relates to compounds, compositions, and methods useful for modulating matrix metalloproteinase (e.g., MMP13) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of MMP13 gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of MMP13 genes.
Public/Granted literature
Information query